Développement de la spectrométrie rétinienne pour l'identification de nouveaux biomarqueurs précoces de la maladie de Parkinson

帕金森病新生物标志物鉴定光谱研究的开发

• 批准号: 538422-2018
• 负责人: Parent, Martin
• 金额: $ 3.01万
• 依托单位: Université Laval
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=688411
• 关键词: veloppement; de; la; spectrom; trie

The regulation of retinal blood flow and oxygenation are recognized as root causes of the majority of ocular diseases, such as glaucoma. There is thus a huge interest in measuring these parameters in vivo, ideally using non-invasive methods. Retnia's technology, based on optical spectroscopy, enables such non-invasive measurements in laboratory and clinical settings. Recently, there has been growing evidence that many neurodegenerative diseases also have an effect on the retina, which is part of the central nervous system. Of the many neurodegenerative diseases that could possibly be sensed in the eye, Parkinson's disease (PD) stands out, due to the retina's similarities to the substantia nigra, a midbrain region that is known to degenerate in PD. PD affects more than 100 000 Canadians and is considered as the second most common neurodegenerative disease. Some disease-modifying treatments exist but drugs that have been tested have provided disappointing results. This can be largely explained by the fact that the cardinal symptoms of PD typically manifest only when more than half of dopaminergic neurons in the substantia nigra are lost. Therefore, early biomarkers of PD are urgently needed to succeed in disease-modifying therapies. In the proposed research project, we will use Retnia's multimodal imaging device to perform spectroscopy on the retina of healthy and parkinsonian monkeys in order to identify and locate optical biomarkers in the form of hemoglobin and melanin retinal content and abnormalities, for early detection of PD.

视网膜血流和氧合的调节被认为是大多数眼部疾病（例如青光眼）的根本原因。因此，理想情况下，使用非侵入性方法在体内测量这些参数有很大的兴趣。 Retnia的技术基于光谱法，可以在实验室和临床环境中进行这种非侵入性测量。最近，越来越多的证据表明，许多神经退行性疾病也对视网膜有影响，这是中枢神经系统的一部分。由于视网膜与视网膜与黑质Nigra的相似性，帕金森氏病（PD）可能会在眼中感受到许多神经退行性疾病，这是一个已知在PD中退化的中脑区域。 PD影响了100万多名加拿大人，被认为是第二常见的神经退行性疾病。存在一些改良疾病的治疗方法，但是经过测试的药物提供了令人失望的结果。这可以在很大程度上通过以下事实来解释：PD的基本症状通常只有在丢失了黑质中超过一半的多巴胺能神经元时才能表现出来。因此，迫切需要PD的早期生物标志物在改善疾病疗法方面取得成功。在拟议的研究项目中，我们将使用Retnia的多模式成像装置对健康和帕金森猴的视网膜进行光谱，以识别和定位以血红蛋白和黑色素视网膜含量和异常形式的光学生物标志物，以早期检测PD。